The University of California San Diego Health System, a leader in chronic thromboembolic pulmonary hypertension (CTEPH) research and patient care, has just received a generous grant to fund the recent launch of the country’s first CTEPH registry. The $7.6 million grant comes from pharmaceutical giant Bayer HealthCare in time for the November Pulmonary…

Bayer HealthCare recently launched a contest with the goal of raising awareness about pulmonary hypertension (PH) and gathering support for PH patients and their families. Of particular focus in this contest is a type of PH called CTEPH, or chronic thromboembolic pulmonary hypertension. Breathless Moments…

Patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) have higher serum levels of antibodies against the EDX2 and PHAX proteins, according to research which suggests that these autoantibodies could be used as diagnostic tools for both diseases. The study, “Elevated levels…

The gut microbiota of patients with chronic thromboembolic pulmonary hypertension (CTEPH) differs from that of healthy individuals, and this perhaps explains why there also is more inflammation, a Japanese study found. The findings provide new information on the way CTEPH may develop. The study, “Altered gut microbiota and…

The matrix around the heart’s cells does not shrink and may continue to undergo changes after pulmonary endarterectomy, or PEA, a surgery to remove blood clots from the pulmonary arteries that supply the lungs, a small study found. Researchers suggest that fibrosis, or scarring, may explain why the heart’s size…

Among people with chronic thromboembolic pulmonary hypertension (CTEPH), certain anticoagulants may reduce the risk of serious bleeding more than others, a new study shows. The study, “Real-life data of direct anticoagulant use, bleeding risk and venous thromboembolism recurrence in chronic thromboembolic pulmonary hypertension patients: an observational…

A new procedure, performed at Northwestern Memorial Hospital in Illinois, successfully treated a patient with pulmonary hypertension (PH) caused by blood clots formed in the lung vessels, a condition referred to as chronic thromboembolic pulmonary hypertension (CTEPH).

Among the fives types of PH, Pulmonary Arterial Hypertension (PAH) is recognized as a serious unmet medical need in terms of viable treatments, due to the progressive and life-threatening characteristics of the disease.  PAH patients experience symptoms where blood pressure in the pulmonary arteries is significantly heightened due to vasoconstriction, frequently…

According to an article entitled “Mosaic Pattern of Lung Attenuation on Chest CT in Patients with Pulmonary Hypertension”  published in the journal Disease on September 7, 2015 and authored by Kamonpun Ussavarungsi et al., a mosaic lung attenuation pattern can be observed in the chest…

Insulin resistance or IR — a reduced response of body tissues to insulin, a hormone that regulates blood sugar levels — was found to correlate with disease severity in people with chronic thromboembolic pulmonary hypertension (CTEPH), according to a new study from researchers in China. Further, the team determined that…

Estimated survival in patients with either pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) is worse if they also have atrial arrhythmias, according to a new U.S. study. The study, “Atrial arrhythmias are associated with increased mortality in pulmonary arterial hypertension,” was published…

Worse measures of blood flow, arterial oxygenation, and cardiac function may underlie the poor clinical condition of chronic thromboembolic pulmonary hypertension (CTEPH) patients who also have obstructive sleep apnea (OSA), according to a new study. The research, “Obstructive sleep apnea in patients with chronic thromboembolic pulmonary…